Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corp. (Nasdaq: OCX) is a diagnostics technology company focused on molecular tests for organ transplantation and oncology, and its news flow reflects this dual focus. Company updates frequently describe progress toward commercializing a dd-cfDNA-based transplant rejection monitoring test kit, including clinical trial milestones, regulatory interactions, and reimbursement developments. Oncocyte also reports on the use of its proprietary assays in peer-reviewed studies and collaborations with leading transplant centers and research institutions.
Investors and clinicians following OCX news can expect regular announcements about the GraftAssure transplant portfolio, which includes the GraftAssureCore lab-developed test, the GraftAssureIQ research-use-only kit, and the planned GraftAssureDx in-vitro diagnostic kit. Recent releases have highlighted Medicare reimbursement improvements for the company’s lab-developed transplant assay, expanded coverage for specific high-risk patient groups, and adoption of GraftAssure research kits by transplant centers in the United States, Europe, and Southeast Asia.
Oncocyte’s news also covers scientific publications that use its proprietary assays to study transplant biology, such as data in Transplantation Direct examining dd-cfDNA levels and kidney allograft biopsies. In oncology, updates have discussed the role of the DetermaIO gene expression test in studies like NeoTRIP in triple negative breast cancer, as well as the DetermaCNI blood-based monitoring tool.
In addition, OCX news items report on quarterly and annual financial results, pharma services revenue from its CLIA-certified Nashville lab, capital raises, and its strategic partnership with Bio-Rad Laboratories. Corporate communications may also include participation in healthcare and diagnostics conferences and plans related to corporate renaming. For those tracking the company, the news stream provides insight into clinical, regulatory, scientific, and capital markets developments affecting Oncocyte’s transplant and oncology diagnostics programs.
Oncocyte Corporation (Nasdaq: OCX) announced that its DetermaCNI test has demonstrated higher sensitivity in detecting cancer recurrence compared to standard biomarkers, showcasing 91% sensitivity at diagnosis and 86% sensitivity during treatment, with a low false positive rate of 5%. This blood-based test offers a genome-wide assessment without the need for tissue samples, making it an innovative solution for cancer monitoring, particularly for ovarian cancer patients, addressing significant unmet needs in treatment evaluation.
Oncocyte Corporation (OCX) announced significant advancements for its DetermaIO test at the SABCS 2021, showcasing its ability to predict responses to immunotherapies in triple negative breast cancer (TNBC). The test achieved a 92% concordance with RNA-sequencing data, emphasizing its reliability across different platforms. It is expected to enhance patient outcomes by identifying candidates for immunotherapy, thus addressing a critical unmet need. DetermaIO has previously demonstrated efficacy in other cancers, reinforcing its potential for pan-cancer diagnostic testing globally.
Oncocyte Corporation (Nasdaq: OCX) has successfully completed the second phase of a three-step technology transfer under its Exclusive Sublicense Agreement with Burning Rock Biotech. This milestone includes a $2M payment and allows Burning Rock to commercially launch the DetermaRx™ test for early-stage lung cancer in China, where the potential patient population is significantly larger than in the U.S. The third phase, involving software validation and another $1M payment, is expected by April 30, 2022.
Oncocyte Corporation (Nasdaq: OCX) announced a business update call scheduled for December 14, 2021, focusing on its DetermaIO immunotherapy response prediction test and TheraSure Transplant Monitor test. The management team will provide an update on the pipeline and highlight key milestones for major products anticipated in 2022.
DetermaIO is a gene expression test that predicts responses to immuno-oncology therapies, while TheraSure monitors organ transplant health using a blood test, reducing the need for invasive procedures.
Oncocyte Corporation (Nasdaq: OCX) announced new data on its DetermaIO test, which predicts response to immunotherapy in cancers like lung and triple-negative breast cancer. The test will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 8 and 9. The DetermaIO test assesses the entire tumor microenvironment to help identify suitable patients for immunotherapy. Oncocyte aims to improve cancer treatment outcomes through precision diagnostics and will provide further results after the market closes on December 9, 2021.
Oncocyte Corporation (OCX) announced the clinical launch of DetermaIO, the first immunotherapy response prediction test that assesses the tumor microenvironment, outperforming PD-L1 IHC. Recent data on Triple Negative Breast Cancer confirms its efficacy. The company reported a 65% year-over-year growth in test volume and raised its transplant monitoring capabilities with new IP. For Q3 2021, revenues reached approximately $1.0 million, a 77% increase from last year, though net losses grew to $13.8 million, or ($0.15) per share.
Oncocyte Corporation (Nasdaq: OCX) has launched the DetermaIO test, the first immunotherapy clinical test that evaluates the tumor microenvironment to predict patient responses to immunotherapy. Clinical studies have shown DetermaIO's accuracy in identifying potential responders, offering significant advantages over existing biomarkers like PD-L1.
The test aims to assist over one million patients annually in the U.S. in selecting effective immunotherapy treatments. Initial interest from physicians is high, and DetermaIO will be integrated with other tests for comprehensive patient management.
Oncocyte Corporation (Nasdaq: OCX) announced the issuance of U.S. Patent No. 11,155,872 for its Therasure Transplant Monitor, enhancing its intellectual property in the $2 billion U.S. transplant market. This blood-based test for organ rejection minimizes the need for invasive biopsies. The company plans to launch a lab-developed test (LDT) by Q1 2022 and aims for FDA submission of a kitted product by H1 2023. The patent fortifies Oncocyte's position in blood-based monitoring, and its technology offers cost-effective monitoring for transplant recipients.
Oncocyte Corporation (Nasdaq: OCX) will announce its third-quarter financial results for the period ended September 30, 2021, on November 9, 2021. A conference call is scheduled for the same day at 4:30 pm ET to discuss the results and corporate developments. Oncocyte focuses on precision diagnostics for cancer, with tests like DetermaRx™ and DetermaIO™ aimed at improving patient outcomes. The company emphasizes its commitment to advancing cancer care through proprietary tests and services, which assist in diagnosis, treatment planning, and monitoring.
Oncocyte Corporation (Nasdaq: OCX) has announced the appointment of Gisela A. Paulsen as the new Chief Operating Officer (COO). With over 20 years of experience in global change management and innovation in diagnostics and pharmaceuticals, Paulsen is expected to drive strategic growth and maximize opportunities within the company. Previously, she served as General Manager at Exact Science’s Precision Oncology and held significant roles at Roche/Genentech. Her appointment is anticipated to enhance Oncocyte's operational capabilities at a critical phase for growth in precision oncology diagnostics.